

Amendments to the Claims:

Claim 1 (currently amended): A vaccine comprising a recombinant Sendai virus vector encoding a virus protein of an immunodeficiency virus, wherein the virus protein comprises a protein selected from the group consisting of Pol, gp41, Tat, Rev, Vpu, Vpx, Vpr, Vif, Nef, Gag-Pol fusion protein, and a part of any of them, and wherein the vaccine induces a cellular immune response specific to the virus protein.

Claim 2 (previously presented): A vaccine comprising a Sendai virus vector encoding a Gag protein or a part of it, wherein the vaccine induces a cellular immune response specific to the Gag protein or the part of it.

Claim 3 (original): The vaccine of claim 1, wherein the Sendai virus vector is defective in the V gene.

Claim 4 (original): The vaccine of claim 2, wherein the Sendai virus vector is defective in the V gene.

Claim 5 (currently amended): A method for vaccination, the method comprising ~~inoculating a vaccine comprising a~~ intranasally administering a recombinant Sendai virus vector encoding a virus protein of an immunodeficiency virus.

Claim 6 (canceled)

Claim 7 (currently amended): The method of claim 5, wherein the vaccine is ~~inoculated at least once in~~ vaccination comprises multiple vaccine inoculations and the recombinant Sendai virus vector is inoculated at least once.

Claim 8 (canceled)

Claim 9 (currently amended): The method of ~~claim 7~~ claim 5, wherein the method further comprises the ~~steps of (a) step of~~ inoculating a DNA vaccine comprising a DNA encoding the genome of the immunodeficiency virus ~~and then (b) inoculating before the~~ inoculation of the Sendai virus vector ~~encoding a virus protein of an immunodeficiency virus.~~

Claim 10 (canceled)

Claim 11 (currently amended): A method for inducing a cellular immune response specific to a virus protein of an immunodeficiency virus *in vitro*, the method comprising the steps of (a) introducing a recombinant Sendai virus encoding the virus protein into an

antigen presenting cell and (b) contacting the antigen presenting cell with a T helper cell and cytotoxic T cell, thereby inducing a cellular immune response.

Claim 12 (previously presented): The method of claim 11, wherein the virus protein comprises a protein selected from the group consisting of Pol, gp41, Tat, Rev, Vpu, Vpx, Vpr, Vif, Nef, Gag-Pol fusion protein, and a part of any of them.

Claim 13 (previously presented): The method of claim 11, wherein the virus protein comprises a Gag protein or a part of it.

Claim 14 (previously presented): The method of claim 11, wherein the antigen presenting cell is an autologous herpes virus papio-immortalized B lymphoblastoid cell.

Claim 15 (previously presented): The method of claim 11, wherein said contacting step comprises co-culturing the antigen presenting cell with the T helper cell and the cytotoxic T cell in a medium.

Claim 16 (currently amended): A composition comprising a carrier and a recombinant Sendai virus vector encoding a virus protein of an immunodeficiency virus, wherein the virus protein comprises a protein selected from the group consisting of Pol, gp41, Tat,

Rev, Vpu, Vpx, Vpr, Vif, Nef, Gag-Pol fusion protein, and a part of any of them, and wherein the vaccine induces a cellular immune response specific to the virus protein.

Claim 17 (currently amended): A composition comprising a carrier and a Sendai virus vector encoding a Gag protein or a part of it, wherein the ~~vaccine~~ composition induces a cellular immune response specific to the Gag protein or the part of it.

Claim 18 (previously presented): The composition of claim 16, wherein the Sendai virus vector is defective in the V gene.

Claim 19 (previously presented): The composition of claim 17, wherein the Sendai virus vector is defective in the V gene.

Claim 20 (currently amended): A method for inducing a cellular immune response specific to a virus protein of an immunodeficiency virus in an animal, the method comprising ~~inoculating a composition comprising a carrier and a~~ the step of intranasally administering a recombinant Sendai virus vector encoding the virus protein.

Claim 21-23 (canceled)

Claim 24 (currently amended): The method of ~~claim 22~~ claim 20, wherein the method further comprises the steps of (a) the step of inoculating a DNA vaccine comprising a DNA encoding the genome of the immunodeficiency virus and then (b) inoculating before the administration of the Sendai virus vector.

Claim 25 (canceled)

Claim 26 (previously presented): The method of claim 24, wherein the genome is defective in env gene and nef gene.

Claim 27 (canceled)

Claim 28 (previously presented): The method of claim 20, wherein the virus protein comprises a protein selected from the group consisting of Pol, gp41, Tat, Rev, Vpu, Vpx, Vpr, Vif, Nef, Gag-Pol fusion protein, and a part of any of them.

Claim 29 (currently amended): The method of claim 20, wherein the virus protein comprises the Gag protein or a part of it.

Claim 30 (currently amended): The method of claim 20, wherein the animal is a

~~mammalian animal~~ mammal.

Claim 31 (currently amended): The method of claim 30, wherein the ~~mammalian animal~~ mammal is a non-human primate.

Claim 32 (currently amended): The method of claim 30, wherein the ~~mammalian animal~~ mammal is a human.

Claim 33 (currently amended): A method for repressing propagation of an immunodeficiency virus in an animal, the method comprising ~~inoculating a composition comprising a carrier and a~~ intranasally administering a Sendai virus vector encoding the virus protein.

Claim 34-36 (canceled)

Claim 37 (currently amended): The method of ~~claim 35~~ claim 30, wherein the method further comprises the steps of (a) the step of inoculating a DNA vaccine comprising a DNA encoding the genome of the immunodeficiency virus ~~and then (b) inoculating~~ before the administration of the Sendai virus vector.

Claim 38 (canceled)

Claim 39 (previously presented): The method of claim 37, wherein the genome is defective in env gene and nef gene.

Claim 40 (canceled)

Claim 41 (previously presented): The method of claim 33, wherein the virus protein comprises a protein selected from the group consisting of Pol, gp41, Tat, Rev, Vpu, Vpx, Vpr, Vif, Nef, Gag-Pol fusion protein, and a part of any of them.

Claim 42 (currently amended): The method of claim 33, wherein the virus protein comprises the Gag protein or a part of it.

Claim 43 (currently amended): The method of claim 33, wherein the animal is a ~~mammalian animal~~ mammal.

Claim 44 (currently amended): The method of claim 43, wherein the ~~mammalian animal~~ mammal is a non-human primate.

Claim 45 (currently amended): The method of claim 43, wherein the ~~mammalian animal~~ mammal is a human.

Claim 46 (new): The vaccine of claim 1, wherein the Sendai virus vector is defective in an envelope gene.

Claim 47 (new): The vaccine of claim 2, wherein the Sendai virus vector is defective in an envelope gene.

Claim 48 (new): The vaccine of claim 46, wherein the envelope gene is F gene.

Claim 49 (new): The vaccine of claim 47, wherein the envelope gene is F gene.

Claim 50 (new): The method of claim 5, wherein the Sendai virus vector is defective in an envelope gene.

Claim 51 (new): The method of claim 50, wherein the envelope gene is F gene.

Claim 52 (new): The method of claim 11, wherein the Sendai virus vector is defective in an envelope gene.



Claim 53 (new): The method of claim 52, wherein the envelope gene is F gene.

Claim 54 (new): The composition of claim 16, wherein the Sendai virus vector is defective in an envelope gene.

Claim 55 (new): The composition of claim 17, wherein the Sendai virus vector is defective in an envelope gene.

Claim 56 (new): The composition of claim 54, wherein the envelope gene is F gene.

Claim 57 (new): The composition of claim 55, wherein the envelope gene is F gene.

Claim 58 (new): The method of claim 20, wherein the Sendai virus vector is defective in an envelope gene.

Claim 59 (new): The method of claim 58, wherein the envelope gene is F gene.

Claim 60 (new): The method of claim 33, wherein the Sendai virus vector is defective in an envelope gene.

Claim 61 (new): The method of claim 60, wherein the envelope gene is F gene.